Global Orphan Drugs for AML Market 2018 Key Players: Noventia Pharma Srl, Janssen-Cilag International N V, Ariad Pharma Ltd, Novartis Europharm Ltd, Celgene Europe Limited, Otsuka Pharmaceuticals,.

Orphan Drugs for AML Market:

WiseGuyReports.com adds “Orphan Drugs for AML Market 2018 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting to ”reports to its database.

Executive Summary

Adroit Healthcare Services 'Orphan drugs for AML - Competitive Landscape and Market, Market Access Potential, Pricing & Pipeline Analysis, 2018' provides the comprehensive list of orphan drugs that are indicated for acute myeloid leukemia. The main objective of this report is to provide a comprehensive secondary research and market analysis of orphan drugs that are indicated for treating acute myeloid leukemia. This report also includes the market access and reimbursement challenges across EU5 and US. With Vidaza indicated as standard of care and the low dose cytabine indicated as well (off label), there are opportunities and challenges involved in the new drug development. Understanding the market access challenges of the recently approved drugs, there are many key takeaways which are presented in the current report. This report also includes the pipeline products that are in Phase 3, Phase 2, Phase 1, & preclinical stage of development. This report also provides comprehensive research on the companies that are working on AML inhibitors including the deals and acquisitions.

The report is built with the in-depth secondary research, understanding the market access aspects across the different countries.

Noventia Pharma Srl
Janssen-Cilag International N V
Ariad Pharma Ltd
Novartis Europharm Ltd
Celgene Europe Limited
Otsuka Pharmaceuticals
Daiichi-Sankyo
Arog pharmaceuticals
Cyclacel pharmaceuticals
Sunesis pharmaceuticals
Boehringer Ingelheim
Onconova
Sanofi
Request Sample Report @ https://www.wiseguyreports.com/sample-request/3077000-orphan-drugs-for-aml-competitive-landscape-and-market

Table of Content

1. Disease Landscape 
    1.1 Acute Myeloid Leukemia 
    1.2 Etiology and Pathophysiology 
    1.3 Key findings 
    1.4 Disease overview 
    1.5 Etiology 
    1.6 Pathogenesis 
    1.7 Key pathways and drug targets 
2. Key updates: 
• March 2018 
• December 2017 
• September 2017 
3. Executive summary 
    3.1 Key findings 
4. Market Outlook 
    4.1 Key findings 
    4.2 Market drivers and constraints 
    4.3 SWOT analysis 
5. Orphan drug 
    5.1 US orphan drug approval 
    5.2 EU orphan drug approval 
    5.3 Japan orphan drug approval 
6. Epidemiology Overview 
    6.1 Introduction Key Findings 
    6.2 Epidemiology populations total prevalent cases 
7. Current treatment overview 
    7.1 Key findings 
    7.2 Orphan drugs available to treat AML 
    7.3 Product specific page 
      7.3.1 Ceplene 
      7.3.2 Dacogen 
      7.3.3 Iclusig 
      7.3.4 Rydapt 
      7.3.5 Vidaza 
8. Companies working on AML drugs 
    8.1 Collaborations, deals and acquisitions 
9. Emerging treatment overview 
    9.1 Key findings 
    9.2 Late stage products 
    9.3 Phase 2 products 
    9.4 Early state products 
10. Access and Reimbursement Overview 
    10.1 Region-Specific Reimbursement Practices 
      10.1.1 United states 
      10.1.2 EU5 
11. Appendix 
Table 1: US and EU drug approvals for Orphan drugs 
Table 2: Orphan drugs available to treat AML 
Table 3: Comparative HTA opinions 
Table 4: Collaborations, deals and acquisitions 
Table 5: Late stage products 
Table 6: Phase 2 products 
Figure 1: US and EU drug approvals for Orphan drugs 
Figure 2: Orphan drugs available to treat AML 
Figure 3: Comparative HTA opinions 
Figure 4: Pricing of drugs that are indicated for AML 
Figure 5: Late stage products 
Figure 6: Phase 2 products 
Figure 7: Assessment based on route of administration 
Figure 8: Assessment by molecule type

Continuous…

For further information on this report, visit – https://www.wiseguyreports.com/reports/3077000-orphan-drugs-for-aml-competitive-landscape-and-market

Contact Us:

Norah Trent           

sales@wiseguyreports.com

Ph: +1-646-845-9349 (US); +44 208 133 9349 (UK)

About Us:
Wise Guy Reports Is Part Of The Wise Guy Consultants Pvt. Ltd. And Offers Premium Progressive Statistical Surveying, Market Research Reports, Analysis & Forecast Data For Industries And Governments Around The Globe. Wise Guy Reports Features An Exhaustive List Of Market Research Reports From Hundreds Of Publishers Worldwide. We Boast A Database Spanning Virtually Every Market Category And An Even More Comprehensive Collection Of Market Research Reports Under These Categories And Sub-Categories.

Addres:
WISEGUY RESEARCH CONSULTANTS PVT LTD
Office No. 528, Amanora Chambers
Pune - 411028
Maharashtra, India
Phone :+91 841 198 5042

This release was published on openPR.